TY - JOUR
T1 - Treatment of immunoglobulin light chain amyloidosis
AU - Gertz, Morie A.
AU - Zeldenrust, Steven R.
N1 - Funding Information:
Potential Competing Interests: Dr Dispenzieri has received research support from Celgene, Millenium, Pfizer, Jannsen, and Alnylam. Dr Kumar as received research support from Celgene, Novartis, Onyx, Millennium, Sanofi, and Janssen. Dr Reeder has received research support from Celgene, Novartis, and Millennium. Dr Mikhael has received research support from Celgene, Onyx, Abbvie, and Sanofi. Dr Grogan has received research support from Pfizer; and consulting fees from Prothena. Dr Fonseca has a patent for the prognostication of multiple myeloma based on genetic categorization of the disease; has received consulting fees from Celgene, Genzyme, BMS, Bayer, Lilly, Onyx, Binding Site, Novartis, Sanofi, Millennium, and AMGEN; has sponsored research from Onyx; and is a member of the scientific advisory board of Applied Biosciences. Dr Ailawadhi has received honoraria from Millennium and Amgen. Dr Bergsagel has received research support from Novartis and Constellation Pharmaceuticals; and consultant fees from Amgen, Janssen, Sanofi-Aventis, Mundipharma, and BMS. Dr Stewart has received research support from Celgene and Millennium Pharmaceuticals; and consulting fees from Novartis and Millennium Pharmaceuticals. Dr Gertz has received research support from ISIS and Prothena; and honoraria from Celgene, Millennium Pharmaceuticals, and Novartis.
Funding Information:
Grant Support: This work was supported in part by the Robert A. Kyle Hematologic Malignancies Program, the Jabbs Foundation, and the Predolin Foundation.
PY - 2009
Y1 - 2009
N2 - No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Therapies shown to be effective are based on alkylators, dexamethasone, or combinations of an alkylator and steroids. In the past 5 years, novel agents previously shown to be effective in multiple myeloma (eg, thalidomide, lenalidomide, and bortezomib) have been shown to have efficacy in the management of AL amyloidosis. Predictors of outcome include the serum brain natriuretic peptide, the number of organs involved, and the severity of cardiac involvement detected by echocardiography. Virtually all patients are candidates for a trial of therapy, and it is possible to find a nontoxic regimen that can be administered to virtually any patient.
AB - No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients. Therapies shown to be effective are based on alkylators, dexamethasone, or combinations of an alkylator and steroids. In the past 5 years, novel agents previously shown to be effective in multiple myeloma (eg, thalidomide, lenalidomide, and bortezomib) have been shown to have efficacy in the management of AL amyloidosis. Predictors of outcome include the serum brain natriuretic peptide, the number of organs involved, and the severity of cardiac involvement detected by echocardiography. Virtually all patients are candidates for a trial of therapy, and it is possible to find a nontoxic regimen that can be administered to virtually any patient.
UR - http://www.scopus.com/inward/record.url?scp=63549126885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63549126885&partnerID=8YFLogxK
U2 - 10.1007/s11899-009-0013-6
DO - 10.1007/s11899-009-0013-6
M3 - Review article
C2 - 20425420
AN - SCOPUS:63549126885
SN - 1558-8211
VL - 4
SP - 91
EP - 98
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 2
ER -